Journal article icon

Journal article

Paclitaxel with or without trametinib or pazopanib in advanced wild-type BRAF Melanoma (PACMEL): a multicentre, open-label, randomised, controlled phase II trial

Abstract:

Backround: Advanced melanoma treatments often rely on immunotherapy or targeting mutations, with few treatment options for wild-type BRAF (BRAF-wt) melanoma. However, the MAPK pathway is activated in most melanoma, including BRAF-wt. We assessed whether inhibiting this pathway by adding kinase inhibitors trametinib or pazopanib to paclitaxel chemotherapy improved outcomes in patients with advanced BRAF-wt melanoma in a phase II, randomised, open-label trial.

Patients and Methods: P...

Expand abstract
Publication status:
Published
Peer review status:
Peer reviewed

Actions


Access Document


Files:
Publisher copy:
10.1093/annonc/mdy500

Authors


Expand authors...
More from this funder
Funding agency for:
Middleton, M
Grant:
G0601617
GSK/Novartis More from this funder
National Cancer Research Network More from this funder
University of Oxford More from this funder
Publisher:
Oxford University Press Publisher's website
Journal:
Annals of Oncology Journal website
Volume:
30
Issue:
2
Pages:
317–324
Publication date:
2018-11-14
Acceptance date:
2018-10-30
DOI:
EISSN:
1569-8041
ISSN:
0923-7534
Source identifiers:
942833
Pubs id:
pubs:942833
UUID:
uuid:aa8a31a4-139a-4f97-a8f6-792c7a7ffdba
Local pid:
pubs:942833
Deposit date:
2018-11-16

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP